Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Cancer, Cancer - Pancreatic
Seth Kaufman, MD

D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA

To determine whether the addition of erlotinib to gemcitabine improves survival as compared to gemcitabine alone following pancreas adenocarcinoma surgery.

To determine whether the use of fluoropyrimidine and radiotherapy following adjuvant gemcitabine based chemotherapy further enhances survival for such patients who are without evidence of progressive disease after 5 cycles of gemcitabine based chemotherapy. 

Eligible candidates must have had surgery to remove the cancer and staged at T1-3. Patients must be able to maintain adequate oral nutrition. Patients with unstable angina and/or congestive heart failure, transmural myocardial infarction and acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration are ineligible for this study.
Once a week for 12 months

Trial medication is provided at no cost.

Quarterly exams and lab work.

Subjects do not receive monetary compensation.
Rae Lynn Defeo, MBA, CCRP